United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2:00am EDT
Change (% chg)

¥-56 (-2.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo makes 15 bln yen investment
Thursday, 27 Apr 2017 08:00am EDT 

April 27 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::Daiichi Sankyo - making initial 15 billion yen investment to optimize and enhance manufacturing capabilities to support growing antibody drug conjugate pipeline.  Full Article

GSK seeks Japanese approval for shingles vaccine
Tuesday, 18 Apr 2017 04:16am EDT 

April 18 (Reuters) - GlaxoSmithKline Plc ::Gsk vaccine submission for shingles in japan.JV between GSK, Daiichi Sankyo submitted new drug application in Japan seeking approval for candidate shingles vaccine, shingrix.  Full Article

HTG Molecular says entered into master services agreement with Daiichi Sankyo Company
Monday, 17 Apr 2017 07:30am EDT 

April 17 (Reuters) - Htg Molecular Diagnostics Inc :Htg molecular diagnostics - entered into master services agreement with daiichi sankyo company, ltd for work to be performed in htg's veri/o laboratory.Htg molecular diagnostics - initial project includes development of custom assay for detection of nearly 3,000 mrna targets using htg edgeseq technology.  Full Article

Sosei Group unit signs alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED.
Monday, 13 Mar 2017 03:16am EDT 

Sosei Group Corp <4565.T>:Says its subsidiary Heptares signed an alliance for R & D of new small molecule therapeutic drug with DAIICHI SANKYO COMPANY LIMITED. on March 13.  Full Article

Amring Pharmaceuticals says acquired six ANDAs from Luitpold Pharmaceuticals, Alphaforce L.L.P.
Thursday, 9 Mar 2017 11:59am EST 

Amring Pharmaceuticals Inc : Amring pharmaceuticals inc - acquired six andas from luitpold pharmaceuticals inc and alphaforce l.l.p. .Amring pharmaceuticals inc - acquired andas include niche otic and ophthalmic pharmaceuticals.  Full Article

EMA recommends approval of Daiichi Sankyo's anticoagulant
Friday, 24 Feb 2017 07:00am EST 

EU Medicines Agency: EU medicines Agency recommendations for February 2017 . EU Medicines Agency recommends approval Of Daiichi Sankyo's anticoagulant Edoxaban . EU Medicines Agency says adopted positive opinion recommending changes to the terms of the marketing authorisation for the medicinal product Darzalex . EU Medicines Agency recommends approval of Hospira UK Limited's Pemetrexed for treatment of non-small cell lung cancer Source (http://bit.ly/2lCHPks) Further company coverage: [4568.T] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial
Friday, 17 Feb 2017 06:00am EST 

ArQule Inc - : Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma . Study of tivantinib in hepatocellular carcinoma (hcc) did not meet its primary endpoint of improving overall survival .Primary endpoint of study is overall survival.  Full Article

Charleston Laboratories and Daiichi Sankyo receive complete response letter from FDA for CL-108
Friday, 3 Feb 2017 11:00am EST 

Charleston Laboratories : Charleston laboratories, inc. And daiichi sankyo, inc. Receive complete response letter from fda for new drug application for cl-108 (hydrocodone, acetaminophen, promethazine) tablets for oral use .Charleston laboratories - crl stated nda in its present form was not approved and provided guidance on information needed to resolve matters identified.  Full Article

Kite Pharma establishes strategic partnership with Daiichi Sankyo
Monday, 9 Jan 2017 04:23pm EST 

Kite Pharma Inc : Kite Pharma establishes strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (kte-c19) in Japan . Kite Pharma - Daiichi Sankyo will make an upfront payment to kite of $50 million . Kite Pharma says will be eligible to receive future payments totaling up to $200 million for development and commercial milestones . Kite Pharma says is also entitled to receive sales royalties in the low to mid double digit range .Kite pharma - under terms, Daiichi Sankyo will be responsible for development and commercialization of axicabtagene ciloleucel in Japan.  Full Article

R&I affirms Daiichi Sankyo Co Ltd's rating at "AA" and announces negative outlook -R&I
Tuesday, 27 Dec 2016 01:35am EST 

Daiichi Sankyo Co Ltd <4568.T> : Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA" -R&I .Rating outlook negative -R&I.  Full Article


Japan's Daiichi Sankyo denies 2016 takeover bid by AstraZeneca

TOKYO Japanese drugmaker Daiichi Sankyo denied on Thursday it received a takeover bid last year from Britain's AstraZeneca, following speculation that sent its share price soaring as much as 13 percent and triggered a trade suspension.